Poster Session II
Project Type
Poster
Project Funding and Affiliations
L.S. Skaggs Institute for Health Innovation
Faculty Mentor’s Full Name
Erica L. Woodahl
Faculty Mentor’s Department
BMED
Additional Mentor
Shayna R. Killam shayna.killam@umconnect.umt.edu
Abstract / Artist's Statement
Purpose:
Cytochrome P450 2C19 (CYP2C19) is the primary drug-metabolizing enzyme for most proton pump inhibitors (PPIs), commonly prescribed for gastrointestinal disorders such as heartburn. Guidelines developed by the Clinical Pharmacogenetics Implementation Consortium (CPIC) indicate that genetic variants in CYP2C19 may influence PPI response and the likelihood of side effects, and they provide drug and dose recommendations. We systematically evaluated PPI prescribing patterns in Montana’s patient population to inform implementation strategies for pharmacogenetic (PGx)-guided PPI therapy.
Methods:
We analyzed the electronic data from the health information exchange, Big Sky Care Connect, of 1.15 million Montanans between 2017 to 2024. We identified individuals prescribed PPIs with CPIC Level A and B guidelines (e.g., omeprazole, pantoprazole). We quantified the number of participants on PPIs, described PPIs prescribed, and how prescription patterns align across demographic groups (e.g., age, sex, ancestry, ethnicity, and diagnosis).
Main Findings and Significance:
Among 205,345 adults in Montana, 44,930 (21.9%) were prescribed a PPI. Of those, 44,887 (99.9%) were prescribed PPIs with CPIC guidelines, indicating that nearly all PPI users in Montana could potentially benefit from CYP2C19-guided therapy. Of patients on PPIs, 61.8% were female, 60.9% were of European ancestry, and 14.1% were of American Indian or Alaska Native ancestry. Because PPIs are widely prescribed and often used long-term, we can reduce adverse effects and improve symptom control through PGx-guided prescribing. By pinpointing demographic subpopulations with a higher likelihood of benefit from PGx, we aim to support the strategic integration of precision medicine approaches into routine clinical practice across Montana.
Category
Life Sciences
Pharmacogenetics to Enhance Personalized Proton Pump Inhibitor Therapy in Montana
UC South Ballroom
Purpose:
Cytochrome P450 2C19 (CYP2C19) is the primary drug-metabolizing enzyme for most proton pump inhibitors (PPIs), commonly prescribed for gastrointestinal disorders such as heartburn. Guidelines developed by the Clinical Pharmacogenetics Implementation Consortium (CPIC) indicate that genetic variants in CYP2C19 may influence PPI response and the likelihood of side effects, and they provide drug and dose recommendations. We systematically evaluated PPI prescribing patterns in Montana’s patient population to inform implementation strategies for pharmacogenetic (PGx)-guided PPI therapy.
Methods:
We analyzed the electronic data from the health information exchange, Big Sky Care Connect, of 1.15 million Montanans between 2017 to 2024. We identified individuals prescribed PPIs with CPIC Level A and B guidelines (e.g., omeprazole, pantoprazole). We quantified the number of participants on PPIs, described PPIs prescribed, and how prescription patterns align across demographic groups (e.g., age, sex, ancestry, ethnicity, and diagnosis).
Main Findings and Significance:
Among 205,345 adults in Montana, 44,930 (21.9%) were prescribed a PPI. Of those, 44,887 (99.9%) were prescribed PPIs with CPIC guidelines, indicating that nearly all PPI users in Montana could potentially benefit from CYP2C19-guided therapy. Of patients on PPIs, 61.8% were female, 60.9% were of European ancestry, and 14.1% were of American Indian or Alaska Native ancestry. Because PPIs are widely prescribed and often used long-term, we can reduce adverse effects and improve symptom control through PGx-guided prescribing. By pinpointing demographic subpopulations with a higher likelihood of benefit from PGx, we aim to support the strategic integration of precision medicine approaches into routine clinical practice across Montana.